Table 1.
General features of all patients treated with Remdesivir.
| Variables | Overall (N = 220) |
|---|---|
| Mean (±SD) age, years | 60 (46–74) |
| Gender, n (%) | |
| Males Females |
139 (63) 81 (37) |
| Vaccinated, n (%) | 9 (4) |
| Coexisting dismetabolic conditions, n (%) | |
| Hypertension Obesity Type II diabetes |
102 (49) 54 (26) 53 (25) |
| Two or more coexisting conditions, n (%) | 70 (39) |
| Median time (IQR) from symptom onset to Hospitalization, days | 6 (3–8) |
| Median time (IQR) from symptom onset to Remdesivir, days | 7 (4–9) |
| Laboratory tests at admission, median (IQR) | |
| RPC, mg/dL IL-6, pg/mL D-dimer, ng/mL GOT, UI/mL GPT, UI/mL GGT, UI/mL eGFR, mL/min |
48 (21–108) 17 (7–37) 755 (453–1409) 28 (21–40) 28 (19–40) 37 (23–61) 91 (72–107) |
| Oxygen flow required at admission, n (%) | |
| Low flow oxygen HFNC NIV |
187 (85) 25 (11) 8 (4) |
| COVID-19 Severity of Disease, n (%) | |
| Mild Moderate Severe Critical |
15 (7) 108 (49) 79 (35) 18 (8) |
| Progression to Non Invasive Ventilation, n (%) | 60 (27) |
| Outcome, n (%) | |
| Intensive Caare Unit Admission/death Clinical Recovery |
23 (10) 197 (89) |
| Virological Recovery, n (%) | 159 (72) |
| Median time (IQR) from first positive to first negative SARS-CoV-2 PCR on nasal-pharyngeal swab, days | 20 (12–28) |
| Median (IQR) duration of hospital stay, days | 15 (11–23) |
SD: Standard Deviation; IQR: Interquartile Range (Q1 to Q3); CRP: C Reactive Protein; IL-6: Interleukin 6; GOT: Glutamic Oxaloacetic Transaminase; GPT: Glutamic Piruvic Transaminase; GGT: Gamma Glutammil Transpeptidase; eGFR: esteemed Glomerular Filtration Rate.